Aurisco Pharmaceutical Co.,Ltd.
SSE:605116.SS
21.07 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,475.741 | 1,262.531 | 1,008.076 | 803.363 | 721.44 | 581.633 | 575.412 | 544.402 | 590.422 |
| Cost of Revenue
| 611.536 | 556.558 | 487.676 | 408.644 | 380.537 | 283.271 | 304.624 | 280.255 | 285.394 |
| Gross Profit
| 864.205 | 705.973 | 520.4 | 394.718 | 340.904 | 298.362 | 270.788 | 264.146 | 305.028 |
| Gross Profit Ratio
| 0.586 | 0.559 | 0.516 | 0.491 | 0.473 | 0.513 | 0.471 | 0.485 | 0.517 |
| Reseach & Development Expenses
| 146.34 | 136.886 | 117.264 | 69.351 | 47.353 | 35.101 | 24.655 | 23.526 | 17.905 |
| General & Administrative Expenses
| 68.909 | 71.233 | 50.186 | 41.353 | 24.574 | 20.84 | 16.262 | 96.72 | 157.092 |
| Selling & Marketing Expenses
| 98.021 | 75.947 | 39.863 | 29.7 | 21.346 | 30.244 | 28.35 | 22.267 | 31.107 |
| SG&A
| 166.93 | 147.18 | 90.049 | 71.053 | 45.921 | 51.084 | 44.612 | 118.987 | 188.199 |
| Other Expenses
| 140.435 | 91.179 | 84.735 | 62.036 | 48.86 | 42.848 | -0.476 | -0.031 | 1.491 |
| Operating Expenses
| 453.705 | 375.246 | 292.047 | 202.439 | 142.133 | 129.033 | 109.383 | 180.201 | 212.647 |
| Operating Income
| 410.5 | 330.727 | 241.277 | 193.621 | 187.27 | 170.711 | 164.657 | 70.053 | 111.791 |
| Operating Income Ratio
| 0.278 | 0.262 | 0.239 | 0.241 | 0.26 | 0.294 | 0.286 | 0.129 | 0.189 |
| Total Other Income Expenses Net
| -3.108 | -1.647 | -0.525 | -1.609 | -1.532 | 35.602 | -0.476 | -0.031 | 1.491 |
| Income Before Tax
| 407.392 | 329.08 | 240.752 | 192.011 | 185.738 | 206.313 | 164.181 | 70.022 | 113.282 |
| Income Before Tax Ratio
| 0.276 | 0.261 | 0.239 | 0.239 | 0.257 | 0.355 | 0.285 | 0.129 | 0.192 |
| Income Tax Expense
| 52.6 | 40.01 | 32.541 | 23.73 | 28.511 | 20.183 | 27.351 | 25.546 | 31.446 |
| Net Income
| 354.792 | 289.419 | 210.965 | 168.714 | 157.227 | 186.13 | 136.83 | 44.721 | 86.704 |
| Net Income Ratio
| 0.24 | 0.229 | 0.209 | 0.21 | 0.218 | 0.32 | 0.238 | 0.082 | 0.147 |
| EPS
| 0.89 | 0.71 | 0.53 | 0.42 | 0.39 | 0.46 | 0.38 | 0.12 | 0.23 |
| EPS Diluted
| 0.89 | 0.71 | 0.53 | 0.42 | 0.39 | 0.46 | 0.38 | 0.12 | 0.23 |
| EBITDA
| 511.474 | 414.377 | 313.208 | 247.429 | 223.901 | 234.759 | 161.308 | 88.165 | 101.257 |
| EBITDA Ratio
| 0.347 | 0.328 | 0.311 | 0.308 | 0.31 | 0.404 | 0.28 | 0.162 | 0.171 |